We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+12.81%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.16B
AUM Growth
-$275M
Cap. Flow
-$405M
Cap. Flow %
-18.73%
Top 10 Hldgs %
51.11%
Holding
71
New
13
Increased
14
Reduced
14
Closed
16

Top Buys

Rank Stock Value
1
GH icon
Guardant Health
GH
+$43.1M
2
EDIT icon
Editas Medicine
EDIT
+$30.1M
3
AXSM icon
Axsome Therapeutics
AXSM
+$28.3M
4
ANIP icon
ANI Pharmaceuticals
ANIP
+$22.8M
5
TVTX icon
Travere Therapeutics
TVTX
+$22.2M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$158M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$69.5M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$66.3M
4
BIIB icon
Biogen
BIIB
+$55.6M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$45.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
1
Jazz Pharmaceuticals
JAZZ
$16.1B
$155M 7.17%
1,250,000
+50,000
+4% +$6.73M
INSM icon
2
Insmed
INSM
$22.4B
$137M 6.35%
6,500,000
– –
IONS icon
3
Ionis Pharmaceuticals
IONS
$8.93B
$116M 5.38%
2,834,069
– –
TVTX icon
4
Travere Therapeutics
TVTX
$5.17B
$113M 5.24%
7,370,000
+1,222,732
+20% +$22.2M
GPCR icon
5
Structure Therapeutics
GPCR
$3.37B
$110M 5.09%
2,646,782
– –
IMVT icon
6
Immunovant
IMVT
$7.93B
$103M 4.76%
5,421,330
-2,011,387
-27% -$37.5M
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$98M 4.54%
1,548,252
-151,748
-9% -$9.46M
ALKS icon
8
Alkermes
ALKS
$8.11B
$93.9M 4.35%
3,000,000
– –
SWTX
9
DELISTED
SpringWorks Therapeutics
SWTX
$93M 4.3%
3,546,435
+446,435
+14% +$11.7M
DVAX
10
DELISTED
Dynavax Technologies
DVAX
$84.7M 3.92%
6,557,816
+207,816
+3% +$2.37M
GERN icon
11
Geron
GERN
$898M
$77.6M 3.59%
24,170,966
-2,696,513
-10% -$7.67M
PLRX icon
12
Pliant Therapeutics
PLRX
$65M
$73.4M 3.4%
4,050,000
+627,943
+18% +$14.9M
BCYC
13
Bicycle Therapeutics
BCYC
$269M
$71.9M 3.33%
2,819,045
– –
VRNA
14
DELISTED
Verona Pharma
VRNA
$67.4M 3.12%
3,187,415
– –
GH icon
15
Guardant Health
GH
$19.1B
$53.7M 2.49%
+1,500,000
New +$43.1M
FDMT icon
16
4D Molecular Therapeutics
FDMT
$502M
$50.2M 2.32%
2,778,107
+500,000
+22% +$9.21M
AGEN
17
Agenus
AGEN
$276M
$48M 2.22%
1,500,000
-28,500
-2% -$912K
BEAM icon
18
Beam Therapeutics
BEAM
$2.68B
$42.1M 1.95%
1,317,316
+67,316
+5% +$2.18M
AUTL
19
Autolus Therapeutics
AUTL
$389M
$35.7M 1.65%
15,000,000
– –
NTLA icon
20
Intellia Therapeutics
NTLA
$1.51B
$34.1M 1.58%
835,446
+130,913
+19% +$5.31M
VRDN icon
21
Viridian Therapeutics
VRDN
$2.2B
$30.4M 1.41%
1,279,502
+49,243
+4% +$1.26M
NRIX icon
22
Nurix Therapeutics
NRIX
$2.45B
$29.9M 1.39%
2,997,830
– –
RPTX
23
DELISTED
Repare Therapeutics
RPTX
$28.9M 1.34%
2,727,606
– –
EDIT icon
24
Editas Medicine
EDIT
$399M
$28.4M 1.32%
+3,453,744
New +$30.1M
DYN icon
25
Dyne Therapeutics
DYN
$4.15B
$28.1M 1.3%
2,499,912
+165,279
+7% +$1.95M
1
2 3

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Deep Track Capital held 71 positions worth $2.16B, down 11% from $2.43B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Deep Track Capital withdrew a net $405M in Q2 2023, closing 16 positions and reducing 14 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $158M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier.

Against the trend, Deep Track Capital opened a new position in Guardant Health worth $53.7M.

  • Deep Track Capital's largest Q2 2023 buy was Guardant Health: 1,500,000 shares worth $53.7M.
  • Deep Track Capital added most to Travere Therapeutics in Q2 2023, an estimated $22.2M increase.
  • Deep Track Capital's biggest Q2 2023 reduction was Immunovant, cutting an estimated $37.5M.
  • Deep Track Capital fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $158M.
  • Deep Track Capital's ten largest holdings make up 51% of its $2.16B portfolio in Q2 2023.
  • Deep Track Capital opened 13 new positions and closed 16 in Q2 2023.
  • Deep Track Capital's portfolio value fell 11% quarter-over-quarter to $2.16B.

Based on Deep Track Capital's 13F filing for Q2 2023, filed 14 Aug 2023.